이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Precigen 배당금

배당금 기준 확인 0/6

Precigen 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.38
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Aug 12

Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt

Jul 16

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 PGEN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PGEN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Precigen 시장 대비 배당 수익률

PGEN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PGEN)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (PGEN)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PGEN 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PGEN 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PGEN 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: PGEN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Precigen 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront

President exercised options and sold US$211k worth of stock

Consensus revenue estimates increase by 21%

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022

Precigen, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Consensus estimates of losses per share improve by 14%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Prognosis On Precigen